Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Momenta Phama (MNTA) Misses Q2 EPS by 77c, Revenues Miss
August 2, 2019 7:07 AM EDTMomenta Phama (NASDAQ: MNTA) reported Q2 EPS of ($1.19), $0.77 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $9.2 million.
At Momenta, we are focused on leveraging our teams expertise in the engineering of biologics and our deep... More
